A Saccharomyces boulardii-derived antioxidant protein, thioredoxin, ameliorates intestinal inflammation through transactivating epidermal growth factor receptor
Pharmacological Research · 2024
DOI: 10.1016/j.phrs.2024.107372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Research, 2024. Verfasst von Xiali Qin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, National Key Clinical Specialty, Tianjin Institute of Di…. Hauptthemen laut MEDLINE: ErbB Receptors, Saccharomyces boulardii, Thioredoxins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tianjin Municipal Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Saccharomyces boulardii (Sb) is a probiotic yeast for the treatment of gastrointestinal disorders, including inflammatory bowel disease (IBD). Little is known about the modulatory capacity of the Sb in IBD. Here, we found that oral gavage of Sb supernatant (SbS) alleviated gut inflammation, protected the intestinal barrier, and reversed DSS-induced down-regulated activation of epidermal growth factor receptor (EGFR) in colitis. Mass spectrum analysis showed that thioredoxin (Trx) is one of the critical secreted soluble proteins participating in EGFR activation detected in SbS. Trx exerted an array of significant effects on anti-inflammatory activity, including alleviating inflammation, protecting gut barrier, suppressing apoptosis, as well as reducing oxidative stress. Mechanistically, Trx promoted EGFR ligand gene expression and transactivated EGFR in a concentration-dependent manner. EGFR kinase inhibitor could block Trx-mediated preventive effects of intestinal epithelial injury. Our data suggested that Sb-derived soluble protein Trx could serve as a potential prophylactic, as a novel postbiotic against colitis, which provides a new strategy for the precision prevention and treatment of IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, National Key Clinical Specialty, Tianjin Institute of Digestive Diseases, Tianjin Key Laboratory of Digestive Diseases, Tianji…
Förderung
- Tianjin Municipal Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Qin, X., Zhao, Q., Zhao, Q., Yang, L., Li, W., Wu, J., Liu, T., Zhong, W., Jiang, K., Liu, W., Wang, B., Wang, S., & Cao, H. (2024). A Saccharomyces boulardii-derived antioxidant protein, thioredoxin, ameliorates intestinal inflammation through transactivating epidermal growth factor receptor. Pharmacological Research. https://doi.org/10.1016/j.phrs.2024.107372
Vancouver
Qin X, Zhao Q, Zhao Q, Yang L, Li W, Wu J, et al. A Saccharomyces boulardii-derived antioxidant protein, thioredoxin, ameliorates intestinal inflammation through transactivating epidermal growth factor receptor. Pharmacological Research. 2024. doi:10.1016/j.phrs.2024.107372
BibTeX
@article{Qin2024,
author = {Qin, Xiali and Zhao, Qing and Zhao, Qianjing and Yang, Lijiao and Li, Wanyu and Wu, Jingyi and Liu, Tianyu and Zhong, Weilong and Jiang, Kui and Liu, Wentian and Wang, Bangmao and Wang, Sinan and Cao, Hailong},
title = {A Saccharomyces boulardii-derived antioxidant protein, thioredoxin, ameliorates intestinal inflammation through transactivating epidermal growth factor receptor},
journal = {Pharmacological Research},
year = {2024},
doi = {10.1016/j.phrs.2024.107372}
}
EUVIMED